Biomet Deal Concerns Clouds Call
Doubts over whether Biomet shareholders would approve a leveraged buyout had investors querying the deal on a conference call last Wednesday.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: